BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 31, 2024
See today's BioWorld
See today's BioWorld Asia
Home
» Praxis rallies on $279M China deal for tremor drug, pipeline updates
To read the full story,
subscribe
or
sign in
.
Praxis rallies on $279M China deal for tremor drug, pipeline updates
Jan. 9, 2024
By
Marian (YoonJee) Chu
No Comments
Boston-based Praxis Precision Medicines Inc.’s shares rose nearly 25% on Jan. 8 after it announced a pipeline update and licensing deal for its tremor drug, ulixacaltamide (PRAX-944), with Shanghai’s Tenacia Biotechnology Co. Ltd.
BioWorld
BioWorld Asia
Clinical
Deals and M&A
Neurology/psychiatric
Asia-Pacific
China
